Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MPP Announces Generic Paxlovid Licences For LMICs

Generics Of Pfizer’s Oral COVID-19 Treatment Will Be Supplied To 95 Countries

Executive Summary

A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.

You may also be interested in...



Pfizer Executive On Paxlovid’s Development And Design Journey

Senior Pfizer executive outlines the accelerated development approach for Paxlovid, one that took just 17 months, but was done without cutting any corners for safety and also sought to guard against resistance from the design perspective.

Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval

Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.

Calls For COVID Patent Waivers Persist As Pooling Initiatives Plough Ahead

The formulas for various COVID-19 vaccines remain shrouded in intellectual property protections – one of many factors preventing them from being manufactured in developing nations. Those in favor of upholding IP say that scrapping patents could stifle future innovation, but their opponents believe preserving COVID-19 related IP rights is limiting access to lifesaving medical tools.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel